B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKAA2

MOLECULAR TARGET

protein kinase AMP-activated catalytic subunit alpha 2

UniProt: P54646NCBI Gene: 556313 compounds

PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) is targeted by 13 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKAA2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Adenosine Monophosphate Adenine nucleotide containing1.956
2Proguanil1.956
3Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone1.614
4Quercetin1.393
5Niclosamide1.393
6Berberine1.102
7Ursolic Acid1.102
8Antimycin1.102
9Oleanolic Acid1.102
10Rotenone1.102
11Kaempferols0.691
12Metformin0.691
13Rutin0.691

About PRKAA2 as a Drug Target

PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 13 compounds with documented PRKAA2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKAA2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.